FRM
RVNC

Fox Run Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Fox Run Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,360
Closed -$211K – 1072
2023
Q3 		$211K Buy
+18,360
New +$353K 0.06% 545
2018
Q3 		– Sell
-18,477
Closed -$507K – 869
2018
Q2 		$507K Buy
+18,477
New +$555K 0.16% 242

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fox Run Management's RVNC Position: Q4 2023 in Review

Fox Run Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 18,360 shares — an estimated $211K sold.

Fox Run Management first reported a position in RVNC in Q2 2018 and held it in 2 quarters. The position peaked at $507K in Q2 2018. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • Fox Run Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Fox Run Management sold 18,360 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $211K.
  • Fox Run Management first reported a position in Revance Therapeutics, Inc. in Q2 2018 and held it in 2 quarters.
  • Fox Run Management's Revance Therapeutics, Inc. position peaked at $507K in Q2 2018.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Fox Run Management's 13F filing for Q4 2023, filed 13 Feb 2024.